Mass spectrometry coupled with gas chromatography (GC/ MS) is a powerful analytical tool combining analytical sensitivity and specificity. Its successful application to toxicology and in-born error testing is well known. In the current healthcare environment, clinical laboratories must identify means to reduce costs and improve productivity, including workstation consolidation (1). This applies equally well to the utilization of specialized tools such as GC/MS, and the ability to maximize the productivity of a GC/MS set-up should enhance its economic value to the laboratory.
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We have had in use in our laboratory a GC/MS method for the measurement of methylmalonic acid (MMA) in plasma, based on solid phase anion-exchange extraction, derivatization with cyclohexanol, and separation with quantification using GC/MS (2) . Gabapentin (Neurontin) is a relatively new antiepileptic drug with a structure similar to the neurotransmitter ␥-aminobutyric acid but containing a 6-carbon ring in place of the central methylene group of ␥-aminobutyric acid (3) (4) (5) . Efficacy studies have reported patient serum gabapentin concentrations of 0.5-10.0 mg/L (3). Gabapentin concentrations in serum have been measured using HPLC, gas chromatography, and capillary electrophoresis (6 -9) . Because both gabapentin and MMA are relatively small molecular weight organic acids, we investigated the possibility that the essentials of the MMA method could be utilized to quantify gabapentin.
Initial attempts to utilize the same anion-exchange extraction using the Bond-Elut SAX (Varian) column used in the MMA assay were unsuccessful, probably because an amino group is present in gabapentin. Therefore, an alternative approach using a cation-exchange column was chosen. In addition, it was found that derivatization of the carboxyl group was not necessary for optimized GC performance using the column used in the MMA assay. Therefore, the gabapentin assay was procedurally somewhat simpler than the original MMA method.
Gabapentin and an internal standard [1-(aminomethyl)cycloheptaneacetic acid, M r 185.3] were supplied by Parke-Davis. Gabapentin calibrators were prepared in concentrations of 0 -40.0 mg/L in 50 g/L bovine serum albumin and 9 g/L NaCl in water. The procedure was as follows. Ten microliters of internal standard solution (100 mg/L in water) was added to 0.5 mL of calibrator, specimen, or control, followed by 0.5 mL of 1.0 mol/L HCL. After mixing, samples were applied to a Bond-Elut SCX (Varian) cation-exchange column. The column was washed sequentially twice with 1.0 mL of methanol and twice with 1.0 mL of water at a flow rate of 1-2 mL/min. The column was eluted with 0.25 mL of 2.0 mol/L NH 4 OH in methanol. After the sample was dried down under vacuum at ambient temperature, it was taken up in 75 L of methanol for injection into the GC/MS. A Hewlett-Packard (HP) 5890 Series II gas chromatograph and HP 7673 automated liquid sampler interfaced to a HP 5970B mass-selective detector were utilized. The gas chromatograph was equipped with a HP 5% diphenylpolysiloxane-95% dimethylpolysiloxane capillary column (HP-5; 25 m x 0.22 mm (i.d.) x 0.33-m thick film). Temperature conditions were set similar to the MMA method: the injection temperature was 275°C and the oven temperature was programmed at 15°C/min from 325°C. Helium flow was 52 mL/min. Automated injections of 1 L were made in splitless mode. The massselective detector was operated in the selected ion monitoring mode with mass ions monitored at a dwell time of 100 ms. The retention time for gabapentin was 6.53 min and that for the internal standard was 7.72 min (Fig. 1) . The 153 m/z ion of gabapentin and the 167 m/z ion of the internal standard were monitored. The GC/MS setup required for the gabapentin assay differed from that for the MMA assay only in that the injection port temperature was increased from 225 to 275°C. This allowed both assays to be performed contiguously or simultaneously.
Quantification was based on the ion peak area ratio of gabapentin to that of the internal standard. Ratios from unknowns were compared with a multipoint or singlepoint calibration curve.
The lower limit of detection as determined by repeated measurement of calibrator solution without gabapentin was 0.05 mg/L. Linearity of the method determined by serial dilution of a high calibrator solution was determined to be up to 40 mg/L (y ϭ 0.99x ϩ 0.02, r ϭ 0.999). Results using a single-point calibration curve were found to be equivalent to those using a multipoint curve for a period of at least 3 months. Recovery of 8 mg/L gabapentin added to human serum averaged 101.6% (99.7-105.0%, n ϭ 4). Interference by other antiepileptic drugs, including carbamazepine, carbamazepine-2,3-epoxide, felbamate, ethosuximide, lamotrigine, pentobarbital, phe- Poster Sessions nobarbital, phenytoin, primidone, and valproate was not observed at concentrations exceeding their therapeutic ranges. A survey of library mass spectra indicated that some compounds can yield a 153 m/z or 167 m/z ion on electron impact ionization. These included allobarbital, p-aminosalicylic acid, and diphenylpyraline; however, these compounds were considered highly unlikely components of clinical specimens.
The assay demonstrated a within-run imprecision (CV) of 1.3% at a gabapentin concentration of 4.1 mg/L and a run-to-run total imprecision of 6.9% at 3.0 mg/L and 3.6% at 8.0 mg/L. Comparison of results with those of another GC/MS method (ARUP Laboratory) showed a correlation coefficient of 0.97 with a corresponding regression equation: y ϭ 1.01x Ϫ 0.26 (n ϭ 28, S y͉x ϭ 1.46 mg/L). Clinical values obtained over a 3-month period (n ϭ 107) ranged from Ͻ0.05 to 17.5 mg/L with a median value of 3.0 mg/L.
We conclude that there is substantial merit in using existing GC/MS conditions as a basis for developing assays for chemically similar analytes despite unrelated clinical uses. This is particularly advantageous when the sensitivity and specificity of the mass-selective detector can be exploited relative to other analytical tools such as immunoassay or HPLC. When the productivity of a GC/MS workstation is maximized, the inherent costs related to instrument maintenance, capital depreciation, and columns are amortized over a larger test menu, and unit costs for testing are reduced. At the same time, assays with excellent performance characteristics can be established.
Ultrasensitive Direct Fluorescent Immunoassay for Thyroid Stimulating Hormone, Steven J. Zoha, * Shakuntala Ramnarain, and F.C. Thomas Allnutt (Martek Biosciences Corporation, 6480 Dobbin Rd., Columbia, MD 21045; * author for correspondence: fax 410-740-2985, e-mail martek2001@aol.com) Phycobilisomes are photosynthetic antennae complexes of red algae and cyanobacteria (1-3) . They have been chemically cross-linked in such a way that they remain soluble and stable (4) . These stabilized phycobilisomes (PBXL TM dyes) have large complex weights (between 1.0 ϫ 10 7 and 1.5 ϫ 10 7 Da) and Stokes shifts. They contain a large number of chromophores coordinated to efficiently transfer energy down an energy gradient and emit between 662 and 666 nm. The PBXL-1 dye, used in the thyroidstimulating hormone (TSH) model, contains B-phycoerythrin, R-phycocyanin, and allophycocyanin as its component phycobiliproteins. Each PBXL supramolecular complex can deliver up to 1400 chromophores per binding event without indirect signal generation steps, signal amplification, or enzyme substrates. PBXL dyes provide physical amplification of signal, enabling ultrasensitive direct fluorescent immunodetection of such clinically relevant analytes as TSH.
TSH was used as a model system for a microplate immunoassay because of its clinical importance and high sensitivity requirements. The detection limit of the PBXL based assay was 0.01 mIU/L (6.2 ϫ 10 Ϫ14 mol/L).
We used the following reagents: plate-coating buffer containing 100 mmol/L sodium phosphate (pH 7.4), 150 mmol/L sodium chloride, and 0.5 g/L sodium azide; wash buffer containing 100 mmol/L sodium phosphate (pH 7.4), 150 mmol/L sodium chloride, 0.5 g/L sodium azide, and 0.5 g/L Tween 20; blocking buffer containing 100 mmol/L sodium phosphate (pH 7.4), 150 mmol/L sodium chloride, 0.5 g/L sodium azide, 0.5 g/L Tween 20, and 10.0 g/L bovine serum albumin; assay buffer containing 100 mmol/L sodium phosphate (pH 8.4), 150 mmol/L sodium chloride, 0.5 g/L sodium azide, 0.5 g/L Tween 20, and 10.0 g/L bovine serum albumin; and reagent dilution buffer containing 100 mmol/L sodium phosphate (pH 8.4), 150 mmol/L sodium chloride, 0.5 g/L sodium azide, and 10.0 g/L bovine serum albumin.
The capture antibody was anti-TSH-␤ monoclonal, cat. no. 10-T25, clone no. M94204 (Fitzgerald Industries International). The tag antibody, MAB131, anti-TSH-␤ monoclonal, lot no. 606272 (AbProbe International), was conjugated to PBXL-1 via SATA/sulfo-SMCC heterobifunctional crosslinking chemistry (Pierce) at a 18:1 offered molar ratio.
To make calibrators, purified TSH (Scripps Laboratories, Second IRP for TSH 80/558) was added to a matrix of 60.0 g/L bovine serum albumin, 100 mmol/L sodium phosphate (pH 7.4), and 150 mmol/L NaCl.
Each well of a black 96-well plate (Dynex Technologies) was coated with 150 L of 100 mg/L capture antibody. The plates were covered and allowed to sit at room temperature overnight. The plate-coating buffer was aspirated, and the plates were washed three times with 350 Clinical Chemistry 44, No. 9, 1998 
